TNFAIP3 and Hodgkins lymphoma: This includes inactivating mutations and deletions of TNFAIP3 coding for A20, one of the key inhibitors of the canonical NF-κB pathway, in up to 44% of analyzed cell lines and cHL cases, especially of the nodular sclerosis subtype and in pediatric cases [9,12,13,16,44].